HomeCompareALIM vs MO

ALIM vs MO: Dividend Comparison 2026

ALIM yields 36.10% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALIM wins by $106.9K in total portfolio value
10 years
ALIM
ALIM
● Live price
36.10%
Share price
$5.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$187.1K
Annual income
$29,005.40
Full ALIM calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ALIM vs MO

📍 ALIM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALIMMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALIM + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALIM pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALIM
Annual income on $10K today (after 15% tax)
$3,068.59/yr
After 10yr DRIP, annual income (after tax)
$24,654.59/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $980.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALIM + MO for your $10,000?

ALIM: 50%MO: 50%
100% MO50/50100% ALIM
Portfolio after 10yr
$133.6K
Annual income
$29,582.28/yr
Blended yield
22.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ALIM
Analyst Ratings
9
Buy
4
Hold
Consensus: Buy
Price Target
$5.75
+3.8% upside vs current
Range: $5.50 — $6.00
Altman Z
-1.4
Piotroski
1/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALIM buys
0
MO buys
0
No recent congressional trades found for ALIM or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALIMMO
Forward yield36.10%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$187.1K$80.1K
Annual income after 10y$29,005.40$30,159.17
Total dividends collected$136.3K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$5.75$61.25

Year-by-year: ALIM vs MO ($10,000, DRIP)

YearALIM PortfolioALIM Income/yrMO PortfolioMO Income/yrGap
1← crossover$14,310$3,610.11$10,570$780.30+$3.7KALIM
2$20,140$4,828.13$11,381$1,032.90+$8.8KALIM
3$27,900$6,350.55$12,535$1,392.73+$15.4KALIM
4$38,075$8,222.00$14,193$1,920.91+$23.9KALIM
5$51,227$10,486.45$16,618$2,723.68+$34.6KALIM
6$67,999$13,185.62$20,263$3,993.80+$47.7KALIM
7$89,116$16,357.51$25,936$6,098.36+$63.2KALIM
8$115,389$20,035.00$35,166$9,775.01+$80.2KALIM
9$147,711$24,244.58$51,026$16,597.78+$96.7KALIM
10$187,056$29,005.40$80,113$30,159.17+$106.9KALIM

ALIM vs MO: Complete Analysis 2026

ALIMStock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Full ALIM Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ALIM vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALIM vs SCHDALIM vs JEPIALIM vs OALIM vs KOALIM vs MAINALIM vs PMALIM vs BTIALIM vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.